The suggestion of a correlation existing between the RANKL/RANK/OPG axis and metastatic prostate carcinoma was reported by Chen et al. [149], who described high expression of RANKL and its receptor (RANK) in metastatic cancer, with attendant higher prevalence of these proteins in bone metastasis as compared to lymph node. Here, TNFRSF11A is linked to metastatic prostate carcinoma.